心脏瘤学的新概念
Paola Zagami1,2, Eleonora Nicolò3,4, Chiara Corti3,4
1Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy. paola.zagami@ieo.it.
Cancer treatment and research
|January 4, 2024
概括
乳腺癌治疗可能会导致心脏问题. 早期检测和瘤学家和心脏病学家的团队方法可以改善癌症患者的心血管护理.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 在瘤学瘤学.
- 心脏病学 心脏病学
背景情况:
- 癌症和心血管疾病是全球主要的死亡原因.
- 乳腺癌 (BC) 治疗改善了生存率,但有心血管不良事件 (CV-AEs) 的风险.
- 癌症疗法的心脏毒性可以表现为各种心血管疾病.
研究的目的:
- 审查BC治疗的心脏毒性表现.
- 讨论CV-AE的预防,监测和管理.
- 强调心脏瘤学多学科方法的重要性.
主要方法:
- 关于与BC疗法相关的心脏毒性的文献综述.
- 对化疗,抗HER2药物,CDK4/6抑制剂,PARP抑制剂,抗血管原药和免疫疗法的心脏毒性影响的分析.
- 专注于临床表现,早期发现和管理策略.
主要成果:
- 各种癌症疗法存在心血管不良事件的风险.
- 早期发现CV-AE对于有效治疗和更好的结果至关重要.
- 瘤学家和心脏病学家之间的合作方法是必不可少的.
结论:
- 心脏瘤学对于管理BC患者心脏毒性至关重要.
- 综合监测和及时干预可以减轻CV-AE.
- 了解药物特异性心脏毒性有助于个性化患者护理.
相关概念视频
Pathophysiology of Cardiac Performance
671
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
671
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
160
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
160
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


